v3 Template
G

GRI Bio

Biotechnology / Healthcare La Jolla, CA, USA ~120 employees
Founded
--
Employees (Est.)
~120
8 leaders known
Total Funding
$45.4M
Funding Rounds
7
Last Funding
2025-12-12

About GRI Bio

GRI Bio is a biotechnology company focused on advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases. Their mission is to target earlier key steps in the inflammatory cascade to interrupt disease progression.

Products & Services

GRI-0621:A product in development for the treatment of inflammatory, fibrotic, or autoimmune diseases.
NKT Cell Modulators:Innovative therapies targeting NKT cells to treat inflammatory, fibrotic, and autoimmune diseases.

Specialties

NKT Cell Modulators Inflammatory Diseases Fibrotic Diseases Autoimmune Diseases Clinical Trials for Idiopathic Pulmonary Fibrosis (IPF)

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Public Offering
T: -
FT: Public Offering 		A: 8000000
MR: -
FA: $8.0 million
FAN: 8000000 		D: 2025-12-12
FD: 2025-12-12 		1 investors
2 RT: Public Offering
T: -
FT: Public Offering 		A: 5000000
MR: -
FA: $5.0 million
FAN: 5000000 		D: 2025-04-02
FD: 2025-04-02 		1 investors
3 RT: Public Offering
T: -
FT: Public Offering 		A: 5000000
MR: -
FA: $5.0 million
FAN: 5000000 		D: 2025-04-01
FD: 2025-04-01 		1 investors
4 RT: Warrant Exercise and Offering
T: -
FT: Warrant Exercise and Offering 		A: 13900000
MR: -
FA: $13.9 million
FAN: 13900000 		D: 2024-10-22
FD: 2024-10-22 		1 investors
5 RT: Public Offering
T: -
FT: Public Offering 		A: 4000000
MR: -
FA: $4.0 Million
FAN: 4000000 		D: 2024-06-28
FD: 2024-06-28 		1 investors
6 RT: Public Offering
T: -
FT: Public Offering 		A: 4000000
MR: -
FA: $4 Million
FAN: 4000000 		D: 2024-06-27
FD: 2024-06-27 		-
7 RT: Public Offering
T: -
FT: Public Offering 		A: 5500000
MR: -
FA: $5.5 Million
FAN: 5500000 		D: 2024-02-02
FD: 2024-02-02 		1 investors
Public Offering Latest
2025-12-12
$8.0M
1 investor (Pro only)
Public Offering 2025-04-02
$5.0M
Public Offering 2025-04-01
$5.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

D

David Szekeres

Chairman

M

Marc Hertz, PhD

President, Chief Executive Officer and Director

D

David Baker

Director

R

Roelof Rongen

Director

C

Camilla Simpson

Director

V

Vipin Kumar Chaturvedi, PhD

Chief Scientific Officer

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

GRI Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
gribio.com
Industries
Biotechnology / Healthcare
Company Size
~120 employees (est.)
Locations
La Jolla, CA, USA
LA JOLLA, CA
La Jolla, CA

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro